A review of inflammatory bowel disease from the perspective of Persian medicine

被引:0
|
作者
Hasheminasab, Fatemeh sadat [1 ,2 ]
Azimi, Maryam [3 ,4 ]
机构
[1] Zahedan Univ Med Sci, Pharmacol Res Ctr, Zahedan, Iran
[2] Zahedan Univ Med Sci, Sch Med, Dept Genet, Zahedan, Iran
[3] Kerman Univ Med Sci, Gastroenterol & Hepatol Res Ctr, Kerman, Iran
[4] Kerman Univ Med Sci, Sch Persian Med, Dept Tradit Med, Kerman, Iran
关键词
Inflammatory bowel disease; Persian medicine; Medical history; Avicenna; Iran; Traditional medicine; IRANIAN TRADITIONAL MEDICINE; ULCERATIVE-COLITIS; CHINESE MEDICINE; SPLENIC FUNCTION; DOUBLE-BLIND; EFFICACY; DIFFERENTIATION; PARAMETERS; SYSTEMS; TRIAL;
D O I
10.1016/j.explore.2024.103041
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
The initial descriptions of inflammatory bowel disease (IBD) have been a topic of discussion. Cases of persistent diarrhea have been documented as far back as ancient Greece, with even Hippocrates (similar to 460-370 BCE) exploring various potential causes of diarrhea. Persian medicine was the predominant medical practice in the Eurasia region until the 18th century and had roots in Hippocrates and the ancient civilization of the region. Scholars, such as Avicenna (980-1025 CE), extensively described a disease characterized by intestinal ulcers, bloody diarrhea, and abdominal pain in the early medieval period. While some of the definitions and etiologies of IBD in Persian medicine are based on humoral theories that differ from current medical concepts, recent studies have suggested a potential relationship between the traditional Persian medicine understanding of the disease and IBD. Persian medicine classifies patients with specific diseases into different types of disorders known as dystemperament, with the application of these differences referred to as "syndrome differentiation." These traditional classifications require distinct therapeutic approaches. Research has delved into the molecular bases of the humoral theory and the impact of syndrome differentiation on drug selection for patients, including those with IBD. However, further research is needed to explore the potential effectiveness of Persian medicine in treating IBD and to understand how this ancient classification system can contribute to improved disease management.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
    Caifang Gao
    Lijuan Liu
    Yangyang Zhou
    Zhaoxiang Bian
    Shengpeng Wang
    Yitao Wang
    Chinese Medicine, 14
  • [42] Therapy of inflammatory bowel disease: A surgeon's perspective
    Cohen, Z
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1996, 10 (01): : 43 - 47
  • [43] Evaluating the Indices of Diagnosing Uterine Temperament in Persian Medicine: A Review Study
    Mashhadi, Maryam
    Saeidi, Atefeh
    Tansaz, Mojgan
    Bioos, Soodabeh
    Tabarrai, Malihe
    Kashani, Zahra Darvish-Mofrad-
    Montazeri, Ali
    Saberi, Mohsen
    Mojahedi, Morteza
    Mokaberinejad, Roshanak
    CRESCENT JOURNAL OF MEDICAL AND BIOLOGICAL SCIENCES, 2023, 10 (01): : 2 - 10
  • [44] Metabolomics: A New Perspective to Persian Medicine
    Oskouie, Afsaneh Arefi
    Aliabad, Hossein Soraki
    Zanjani, Rasool Choopani
    Kaveh, Shahpar
    Sadeghi, Sajjad
    Chelavi, Leila Hashemi
    Fayaz, Mohammad
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 498 - 504
  • [45] Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease
    Stefanie Joos
    Chinese Journal of Integrative Medicine, 2011, 17 : 403 - 409
  • [46] Review on Efficacy and Health Services Research Studies of Complementary and Alternative Medicine in Inflammatory Bowel Disease
    Stefanie Joos
    Chinese Journal of Integrative Medicine, 2011, 17 (06) : 403 - 409
  • [47] The use of biosimilars in paediatric inflammatory bowel disease
    Jongsma, Maria Myrthe Elisabeth
    Vulto, Arnold
    de Ridder, Lissy
    CURRENT OPINION IN PEDIATRICS, 2017, 29 (05) : 560 - 565
  • [48] The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease
    Avila-Ribeiro, Pedro
    Fiorino, Gionata
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (44) : 6759 - 6769
  • [49] Oral manifestation in inflammatory bowel disease: A review
    Lankarani, Kamran B.
    Sivandzadeh, Gholam Reza
    Hassanpour, Shima
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (46) : 8571 - 8579
  • [50] Review of fecal biomarkers in inflammatory bowel disease
    Sutherland, Andrew D.
    Gearry, Richard B.
    Frizelle, Frank A.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (08) : 1283 - 1291